Tiago Fauth
Stock Analyst at Wells Fargo
(2.00)
# 2,915
Out of 4,873 analysts
138
Total ratings
36.04%
Success rate
-7.93%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $107 → $138 | $97.22 | +41.95% | 6 | Jun 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $23 → $25 | $13.77 | +81.55% | 2 | Jun 12, 2025 | |
| INSM Insmed | Maintains: Overweight | $107 → $119 | $105.90 | +12.37% | 4 | Jun 11, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $2.29 | +205.68% | 2 | May 28, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $68 → $74 | $49.64 | +49.07% | 2 | May 27, 2025 | |
| INZY Inozyme Pharma | Downgrades: Equal-Weight | $4 | $3.99 | +0.25% | 3 | May 16, 2025 | |
| UTHR United Therapeutics | Downgrades: Equal-Weight | $395 → $314 | $290.10 | +8.24% | 5 | Apr 25, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $112 → $101 | $20.19 | +400.25% | 4 | Mar 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $287 | $325.08 | -11.71% | 5 | Mar 21, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Equal-Weight | $4 → $3 | $1.31 | +129.01% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $13.71 | +89.71% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $5.71 | +197.98% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $88 | $37.16 | +136.81% | 7 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.99 | +125.56% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $6.85 | +221.17% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $55.01 | +36.34% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $2.40 | +2,483.33% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $179.05 | -50.29% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $14.66 | +248.00% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $54.72 | +119.32% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $16.00 | -75.00% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.81 | +398.22% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $5.98 | +335.15% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.68 | +660.87% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $18.61 | +335.37% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.40 | +1,920.20% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.29 | +989.49% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.46 | +7,357.78% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.47 | +4,222.77% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $45.70 | -36.54% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.72 | +658.02% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.25 | +477.78% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.80 | +150.00% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $569.26 | -40.27% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $277.55 | -6.68% | 1 | Apr 28, 2021 |
Verona Pharma
Jun 20, 2025
Maintains: Overweight
Price Target: $107 → $138
Current: $97.22
Upside: +41.95%
Liquidia
Jun 12, 2025
Maintains: Overweight
Price Target: $23 → $25
Current: $13.77
Upside: +81.55%
Insmed
Jun 11, 2025
Maintains: Overweight
Price Target: $107 → $119
Current: $105.90
Upside: +12.37%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.29
Upside: +205.68%
PTC Therapeutics
May 27, 2025
Maintains: Overweight
Price Target: $68 → $74
Current: $49.64
Upside: +49.07%
Inozyme Pharma
May 16, 2025
Downgrades: Equal-Weight
Price Target: $4
Current: $3.99
Upside: +0.25%
United Therapeutics
Apr 25, 2025
Downgrades: Equal-Weight
Price Target: $395 → $314
Current: $290.10
Upside: +8.24%
Tectonic Therapeutic
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $20.19
Upside: +400.25%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $275 → $287
Current: $325.08
Upside: -11.71%
Pliant Therapeutics
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.31
Upside: +129.01%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $13.71
Upside: +89.71%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $5.71
Upside: +197.98%
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $37.16
Upside: +136.81%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $3.99
Upside: +125.56%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $6.85
Upside: +221.17%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $55.01
Upside: +36.34%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.40
Upside: +2,483.33%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $179.05
Upside: -50.29%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $14.66
Upside: +248.00%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $54.72
Upside: +119.32%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $16.00
Upside: -75.00%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.81
Upside: +398.22%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $5.98
Upside: +335.15%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.68
Upside: +660.87%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $18.61
Upside: +335.37%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.40
Upside: +1,920.20%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.29
Upside: +989.49%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.46
Upside: +7,357.78%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.47
Upside: +4,222.77%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $45.70
Upside: -36.54%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.72
Upside: +658.02%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.25
Upside: +477.78%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.80
Upside: +150.00%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $569.26
Upside: -40.27%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $277.55
Upside: -6.68%